Please try another search
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Name | Age | Since | Title |
---|---|---|---|
Tiago Reis Marques | 44 | 2020 | CEO & Director |
Emer Leahy | 55 | 2021 | Independent Director |
Simon Dumesnil | 45 | 2021 | Independent Director |
Daniel R. Weinberger | - | 2022 | Member of Scientific Advisory Board |
Alfred J. Novak | 75 | 2022 | Independent Director |
Lawrence Steinman | 76 | 2020 | Co-Founder, MD & Executive Chairman |
Merit E. Cudkowicz | 60 | 2022 | Member of Scientific Advisory Board |
Luca Rastelli | 56 | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review